PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Romiplostim - Immune thrombocytopenia
PAD Profile : Romiplostim - Immune thrombocytopenia
Keywords :
ITP, NICE, TPO Agonist
Brand Names Include :
Nplate
Traffic Light Status
Status 1 of 2.
Status :
See Below
Formulations :
- Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Guidelines (Local)
31 October 2027
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves the updated ITP pathway.
03 June 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
ITP treatment pathway has been updated to include sequential use of eltrombopag & romiplostim
Associated BNF Codes
09. Nutrition and Blood
09.01.04. Drugs used in platelet disorders